UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000013108
Receipt number R000015282
Scientific Title Efficacy and safety of metformin dose up in Japanese patients with type 2 diabetes inadequately controlled by combination therapy with vildagliptin and low-dose metformin
Date of disclosure of the study information 2014/02/08
Last modified on 2016/11/10 21:49:57

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Efficacy and safety of metformin dose up in Japanese patients with type 2 diabetes inadequately controlled by combination therapy with vildagliptin and low-dose metformin

Acronym

Efficacy and safety of metformin dose up in Japanese patients with type 2 diabetes treated with with vildagliptin (Build Up Study)

Scientific Title

Efficacy and safety of metformin dose up in Japanese patients with type 2 diabetes inadequately controlled by combination therapy with vildagliptin and low-dose metformin

Scientific Title:Acronym

Efficacy and safety of metformin dose up in Japanese patients with type 2 diabetes treated with with vildagliptin (Build Up Study)

Region

Japan


Condition

Condition

type 2 diabetes

Classification by specialty

Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The aim of this study is to compare reduction of HbA1c from baseline between metformin dose up group and non-dose up group in vildagliptin-based therapy and investigate safety and tolerability of high dose of metformin in vildagliptin- based therapy.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

Changes of HbA1c from baseline

Key secondary outcomes

1)Target achievement rate of HbA1c (<6.0%)
2)Changes of insulin, glucagon, C-peptide, proinsulin/insulin rate, DPP-4 activity
3)Symptomatic hypoglycemic events and gastrointestinal disorders
4)inflammatory cytokines and lipid levels


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

metformin dose up is done targeting HbA1c<6.0% and maximum dose is 2250mg/day

Interventions/Control_2

Standard treatment is continued. However, if control is above 7.0%, physicians can increase dose of metformin up tp 1000mg.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

75 years-old >

Gender

Male and Female

Key inclusion criteria

1) Japanese patients with T2DM whose HbA1c 6.5-7.5% (NGSP) even after treatment with combination therapy of vildagliptin (50mg twice daily) and metformin (500-750mg/day) at least 3 months.
2) Over 20 and under 75 years old
3)male and female
4)3) written informed consent from each patient

Key exclusion criteria

1) history of lactic acidosis
2) renal dysfunction
3)under hemodialysis
4)serious liver disease with >100 IU/L in AST and/or ALT
5) Type 1 diabetes
6) under insulin treatment
7) under treatment for cancer
8) proliferative diabetic retinopathy
9)Excess consumption of alcohol
10) gastrointestinal disorders such as diarrhea and vomiting concern to dehydration
11) severe ketosis and diabetic coma or pre-coma
12)serious infective diseases, serious injury, pre- and per-operation
13) during pregnancy and lactation.
14) hypersensitivity of vildagliptin and metformin
15) high dose metformin treatment (>750mg/day)








Target sample size

60


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Akio Kanazawa

Organization

Juntendo university

Division name

Metabolism and Endocrinology

Zip code


Address

2-1-1 Hongo, Bunkyo-ku, Tokyo

TEL

03-3813-3111

Email

akana@juntendo.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Akio Kanazawa

Organization

Juntendo university

Division name

Metabolism and Endocrinology

Zip code


Address

2-1-1 Hongo, Bunkyo-ku, Tokyo

TEL

03-3813-3111

Homepage URL


Email

akana@juntendo.ac.jp


Sponsor or person

Institute

Juntendo university Department of Metabolism and Endocrinology

Institute

Department

Personal name



Funding Source

Organization

Novartis Pharma

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2014 Year 02 Month 08 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2014 Year 02 Month 08 Day

Date of IRB


Anticipated trial start date

2014 Year 02 Month 24 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded

2016 Year 12 Month 05 Day


Other

Other related information



Management information

Registered date

2014 Year 02 Month 08 Day

Last modified on

2016 Year 11 Month 10 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015282


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name